Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3BDY

Dual specific bH1 Fab in complex with VEGF

Summary for 3BDY
Entry DOI10.2210/pdb3bdy/pdb
Related3BE1
DescriptorFab Fragment -Heavy Chain, Fab Fragment -Light Chain, Vascular endothelial growth factor A, ... (5 entities in total)
Functional Keywordsfab complex, angiogenesis, developmental protein, differentiation, glycoprotein, growth factor, heparin-binding, mitogen, secreted, hormone
Biological sourceHomo sapiens (human)
More
Cellular locationSecreted : P15692
Total number of polymer chains3
Total formula weight60554.81
Authors
Bostrom, J.M.,Wiesmann, C.,Appleton, B.A. (deposition date: 2007-11-15, release date: 2008-11-18, Last modification date: 2024-11-13)
Primary citationBostrom, J.,Yu, S.F.,Kan, D.,Appleton, B.A.,Lee, C.V.,Billeci, K.,Man, W.,Peale, F.,Ross, S.,Wiesmann, C.,Fuh, G.
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
Science, 323:1610-1614, 2009
Cited by
PubMed Abstract: The interface between antibody and antigen is often depicted as a lock and key, suggesting that an antibody surface can accommodate only one antigen. Here, we describe an antibody with an antigen binding site that binds two distinct proteins with high affinity. We isolated a variant of Herceptin, a therapeutic monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), on the basis of its ability to simultaneously interact with vascular endothelial growth factor (VEGF). Crystallographic and mutagenesis studies revealed that distinct amino acids of this antibody, called bH1, engage HER2 and VEGF energetically, but there is extensive overlap between the antibody surface areas contacting the two antigens. An affinity-improved version of bH1 inhibits both HER2- and VEGF-mediated cell proliferation in vitro and tumor progression in mouse models. Such "two-in-one" antibodies challenge the monoclonal antibody paradigm of one binding site, one antigen. They could also provide new opportunities for antibody-based therapy.
PubMed: 19299620
DOI: 10.1126/science.1165480
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon